Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Recruiting 1Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 12Other hematologic neoplasm 9Thoracic 6CNS 6Breast 4Dermatologic 1

Conditions

Uveal Melanoma 1Nevus 1Meningeal Neoplasms 1Melanoma 1Lung Neoplasms 1Carcinoma, Non-Small-Cell Lung 1

Interventions

pembrolizumab 65Nivolumab 58Ipilimumab 32Cyclophosphamide 22Specimen Handling 16Magnetic Resonance Spectroscopy 15Biopsy 15relatlimab 13cemiplimab 13fludarabine 12Opdualag 12binimetinib 10Blood Specimen Collection 10aldesleukin 9Radiosurgery 9encorafenib 8Interleukin-2 8atezolizumab 7Immunotherapy 7tebentafusp 6mogamulizumab 6fludarabine phosphate 6Temozolomide 6Surgical Procedures, Operative 6Paclitaxel 6Immunoglobulin G 6CTLA-4 Antigen 6Radiotherapy 5Disulfides 5Bevacizumab 5

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Recruiting × Spinal Puncture × Dermatologic × Clear all
NCT03025256 2026-05-05

Intravenous and Intrathecal Nivolumab in Treating Patients With Leptomeningeal Disease

M.D. Anderson Cancer Center

Phase 1 Recruiting
75 enrolled
DermatologicThoracic

Uveal Melanoma, Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Melanoma, Meningeal Neoplasms, Nevus

Data powered by HemOnc (CC BY 4.0) Colophon âš¡